Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: A case report and review of the literature

Moschowitz E: An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: An undescribed disease. Arch Intern Med. 36:891925. View Article : Google Scholar

Amorosi E and Ultmann J: Thrombotic thrombocytopenic purpura: Report of 16 cases and review of the literature. Medicine. 45:1391966. View Article : Google Scholar

Török TJ, Holman RC and Chorba TL: Increasing mortality from thrombotic thrombocytopenic purpura in the United States-analysis of national mortality data, 1968–1991. Am J Hematol. 50:84–90. 1995. View Article : Google Scholar : PubMed/NCBI

Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC and Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 325:393–397. 1991. View Article : Google Scholar : PubMed/NCBI

Ruggenenti P, Noris M and Remuzzi G: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60:831–846. 2001. View Article : Google Scholar : PubMed/NCBI

Gordon LI and Kwaan HC: Thrombotic microangiopathy manifesting as thrombotic thrombocytopenic purpura hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost. 25:217–221. 1999. View Article : Google Scholar : PubMed/NCBI

Murgo AJ: Cancer- and chemotherapy-associated thrombotic microangiopathyHemolytic-Uremic Syndrome and Thrombotic Thrombocytopenic Purpura (Kidney Disease S v. 10). Kaplan BS, Trompeter RS and Moake JL: 22. Marcel Dekker Ltd; New York: pp. 271–295. 1992

Dlott JS, Danielson CF, BlueHnidy DE and McCarthy LJ: Drug-induced thrombotic thrombocytopenic purpura/haemolytic uremic syndrome: A concise review. Ther Apher Dial. 8:102–111. 2004. View Article : Google Scholar : PubMed/NCBI

Cantrell JE Jr..Phillips TM and Schein PS: Carcinoma-associated hemolytic-uremic syndrome: A complication of mitomycin C chemotherapy. J Clin Oncol. 3:723–734. 1985.PubMed/NCBI

ElGhazal R, Podoltsev N, Marks P, Chu E and Saif MW: Mitomycin-C-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: Cumulative toxicity of an old drug in a new era. Clin Colorectal Cancer. 10:142–145. 2011. View Article : Google Scholar : PubMed/NCBI

Zupancic M, Shah PC and Shah-Khan F: Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 8:634–641. 2008. View Article : Google Scholar

De Smet D, Jochmans K and Neyns B: Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine. Ann Hematol. 87:495–496. 2008. View Article : Google Scholar : PubMed/NCBI

Gardner G, Mesler D and Gitelman HJ: Hemolytic uremic syndrome following cisplatin, bleomycin, and vincristine chemotherapy: A report of a case and a review of the literature. Ren Fail. 11:133–137. 1989. View Article : Google Scholar : PubMed/NCBI

Jiaxin N and Martha PM: Oxaliplatin-induced thrombotic thrombocytopenic purpura: Case report and literature review. J Clin Oncol. 2012.30:312–314. View Article : Google Scholar

Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C and Greenblatt DJ: A method for estimating the propability of advers drug reactions. Clin Pharmacol Ther. 30:239–245. 1981. View Article : Google Scholar : PubMed/NCBI

Sadler JE: Von Willebrand factor, ADAMST13 and thrombotic thrombocytopenic purpura. Blood. 112:11–18. 2008. View Article : Google Scholar : PubMed/NCBI

Zakarija A and Bennett C: Drug-induced thrombotic microangiopathy. Semin Thromb Hemost. 31:681–690. 2005. View Article : Google Scholar : PubMed/NCBI

Tsai HM: Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 14:1072–1081. 2003. View Article : Google Scholar : PubMed/NCBI

Kasi PM: Thrombotic thrombocytopenic purpura and gemcitabine. Case Rep Oncol. 4:143–148. 2011. View Article : Google Scholar : PubMed/NCBI

Gradishar WJ, Vokes EE, Ni K and Panje WR: Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report. Cancer. 66:1914–1918. 1999. View Article : Google Scholar

Siau K and Varughese M: Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: A case report. Med Oncol. 27:1057–1059. 2010. View Article : Google Scholar : PubMed/NCBI

Iams W, Beckermann KE, Neff AT, Mayer IA and Abramson VG: Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early stage HER2⁺ breast cancer. A case report. Med Oncol. 30:5682013. View Article : Google Scholar : PubMed/NCBI

Pisoni R, Ruggenenti P and Remuzzi G: Drug-induced thrombotic microangiopathy: Incidence, prevention and management. Drug Saf. 24:491–501. 2001. View Article : Google Scholar : PubMed/NCBI

Tun NM and Villani GM: Efficacy of rituximab in acute refractory or chronic relapsing non familial idiopathic thrombotic thrombocytopenic purpura: A systematic review with pooled data analysis. J Thromb Thrombolysis. 34:347–359. 2012. View Article : Google Scholar : PubMed/NCBI

Nishijima Y, Hirata H, Himeno A, et al: Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin. Intern Med. 52:1111–1114. 2013. View Article : Google Scholar : PubMed/NCBI